Quanterix Corporation (QTRX) Gross Margin
- Gross margin · 12 months: Value 44.56%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 44.56% | Gross profit / revenue. Period ending 2026-06-30. $68.36M ÷ $153.41M × 100 ≈ 44.56% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 68.36M USD | Gross Profit |
| Revenue | 153.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $68.36M | $153.41M | (m) | 44.56% |
| 2026-03-31 | $65.69M | $144.98M | (m) | 45.31% |
| 2025-12-31 | $64.96M | $138.90M | (m) | 46.77% |
| 2025-09-30 | $67.09M | $130.20M | (m) | 51.53% |
| 2025-06-30 | $70.04M | $125.78M | (m) | 55.68% |
| 2025-03-31 | $80.97M | $135.69M | (m) | 59.67% |
| 2024-12-31 | $83.10M | $137.42M | (m) | 60.47% |
| 2024-09-30 | $80.34M | $133.81M | (m) | 60.04% |
| 2024-06-30 | $74.27M | $129.33M | (m) | 57.42% |
| 2024-03-31 | $73.35M | $125.98M | (m) | 58.22% |
| 2023-12-31 | $70.65M | $122.37M | (m) | 57.73% |
| 2023-09-30 | $66.44M | $116.64M | (m) | 56.96% |
| 2023-06-30 | $59.60M | $111.95M | (m) | 53.24% |
| 2023-03-31 | $49.17M | $104.43M | (m) | 47.09% |
| 2022-12-31 | $46.81M | $105.52M | (m) | 44.36% |
| 2022-09-30 | $50.48M | $109.98M | (m) | 45.89% |
| 2022-06-30 | $54.77M | $111.03M | (m) | 49.33% |
| 2022-03-31 | $59.94M | $112.90M | (m) | 53.09% |
| 2021-12-31 | $61.73M | $110.56M | (m) | 55.83% |
| 2021-09-30 | $60.52M | $106.40M | (m) | 56.88% |
| 2021-06-30 | $66.38M | $110.10M | (m) | 60.29% |
| 2021-03-31 | $57.72M | $97.86M | (m) | 58.98% |
| 2020-12-31 | $48.18M | $86.38M | (m) | 55.78% |
| 2020-09-30 | $40.00M | $76.16M | (m) | 52.52% |
| 2020-06-30 | $25.93M | $59.72M | (m) | 43.41% |
| 2020-03-31 | $27.64M | $60.12M | (m) | 45.97% |
| 2019-12-31 | $26.84M | $56.73M | (m) | 47.30% |
| 2019-09-30 | $25.18M | $51.69M | (m) | 48.71% |
| 2019-06-30 | $23.74M | $47.34M | (m) | 50.15% |
| 2019-03-31 | $20.78M | $42.45M | (m) | 48.96% |
| 2018-12-31 | $17.95M | $37.63M | (m) | 47.69% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $9.99M | $22.87M | (m) | 43.66% |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | $7.75M | $17.59M | (m) | 44.06% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |